Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Soligenix (NASDAQ: SNGX) is advancing its HyBryte鈩� platform to address the growing need for treatments in rare diseases, specifically targeting cutaneous T-cell lymphoma (CTCL), a rare skin cancer affecting primarily older adults. The company has successfully established U.S.-based manufacturing for HyBryte's active ingredient.
This development aligns with healthcare initiatives aimed at improving treatment access and accelerating medical innovation, particularly relevant as over 30 million Americans live with rare diseases. The company's focus on CTCL represents a strategic move to address an underserved therapeutic area, especially significant given the aging American population and the challenges in diagnosing rare diseases in seniors.
Soligenix (NASDAQ: SNGX) sta sviluppando la sua piattaforma HyBryte鈩� per rispondere alla crescente necessit脿 di terapie per malattie rare, concentrandosi in particolare sul linfoma cutaneo a cellule T (CTCL), un raro tumore della pelle che colpisce principalmente gli anziani. L'azienda ha gi脿 avviato con successo la produzione negli Stati Uniti dell'ingrediente attivo di HyBryte.
Questo progresso 猫 in linea con le iniziative sanitarie volte a migliorare l'accesso alle cure e a velocizzare l'innovazione medica, un aspetto particolarmente rilevante considerando che oltre 30 milioni di americani convivono con malattie rare. L'attenzione dell'azienda sul CTCL rappresenta una mossa strategica per affrontare un'area terapeutica poco servita, soprattutto in considerazione dell'invecchiamento della popolazione americana e delle difficolt脿 nella diagnosi delle malattie rare negli anziani.
Soligenix (NASDAQ: SNGX) est谩 avanzando con su plataforma HyBryte鈩� para atender la creciente demanda de tratamientos para enfermedades raras, enfoc谩ndose espec铆ficamente en el linfoma cut谩neo de c茅lulas T (CTCL), un c谩ncer de piel poco com煤n que afecta principalmente a adultos mayores. La compa帽铆a ha establecido con 茅xito la fabricaci贸n en Estados Unidos del ingrediente activo de HyBryte.
Este desarrollo se alinea con las iniciativas de salud destinadas a mejorar el acceso a tratamientos y acelerar la innovaci贸n m茅dica, especialmente relevante dado que m谩s de 30 millones de estadounidenses viven con enfermedades raras. El enfoque de la empresa en el CTCL representa un movimiento estrat茅gico para abordar un 谩rea terap茅utica desatendida, especialmente importante considerando el envejecimiento de la poblaci贸n estadounidense y los desaf铆os en el diagn贸stico de enfermedades raras en personas mayores.
Soligenix (NASDAQ: SNGX)電� 頋穩 歆堩櫂 旃橂鞝滌棎 雽�頃� 歃濌皜頃橂姅 靾橃殧毳� 頃搓舶頃橁赴 鞙勴暣 HyBryte鈩� 頂岆灚韽�鞚� 氚滌爠鞁滍偆瓿� 鞛堨溂氅�, 欤茧 雲鸽厔旄奠棎瓴� 鞓來枼鞚� 氙胳箻電� 頋穩 頂茧秬鞎旍澑 頂茧秬 T靹疙彫 毽柬攧膦�(CTCL)鞚� 歆戩鞝侅溂搿� 瓴儱頃橁碃 鞛堨姷雼堧嫟. 須岇偓電� HyBryte鞚� 頇滌劚 靹彪秳鞐� 雽�頃� 氙戈淡 雮� 鞝滌“毳� 靹标车鞝侅溂搿� 甑稌頄堨姷雼堧嫟.
鞚� 臧滊皽鞚� 旃橂 鞝戧芳靹� 頄レ儊瓿� 鞚橂 順侅嫚 臧�靻嶍檾毳� 氇╉憸搿� 頃橂姅 氤搓贝 鞚橂 鞚措媹靺旐嫲敫岇檧 鞚检箻頃橂┌, 韸鬼瀳 3觳滊 氇� 鞚挫儊鞚� 氙戈淡鞚�鞚� 頋穩 歆堩櫂鞚� 鞎撽碃 鞛堧嫟電� 鞝愳棎靹� 欷戩殧頃╇媹雼�. 須岇偓鞚� CTCL鞐� 雽�頃� 歆戩鞚� 瓿犽牴頇旐晿電� 氙戈淡 鞚戈惮鞕� 雲鸽厔旄奠棎靹� 頋穩 歆堩櫂 歆勲嫧鞚� 鞏措牑鞗�鞚� 瓿犽牑頃� 霑�, 旃橂臧� 攵�臁表暅 攵勳暭毳� 鞝勲灥鞝侅溂搿� 瓿惦灥頃橂姅 鞗�歆侅瀯鞛呺媹雼�.
Soligenix (NASDAQ : SNGX) fait progresser sa plateforme HyBryte鈩� pour r茅pondre au besoin croissant de traitements pour les maladies rares, en ciblant sp茅cifiquement le lymphome cutan茅 脿 cellules T (CTCL), un cancer de la peau rare qui touche principalement les personnes 芒g茅es. L'entreprise a r茅ussi 脿 茅tablir la fabrication aux 脡tats-Unis de l'ingr茅dient actif de HyBryte.
Ce d茅veloppement s'inscrit dans les initiatives de sant茅 visant 脿 am茅liorer l'acc猫s aux traitements et 脿 acc茅l茅rer l'innovation m茅dicale, particuli猫rement pertinent alors que plus de 30 millions d'Am茅ricains vivent avec des maladies rares. L'accent mis par l'entreprise sur le CTCL repr茅sente une d茅marche strat茅gique pour r茅pondre 脿 un domaine th茅rapeutique peu desservi, d'autant plus important compte tenu du vieillissement de la population am茅ricaine et des difficult茅s 脿 diagnostiquer les maladies rares chez les personnes 芒g茅es.
Soligenix (NASDAQ: SNGX) treibt seine 贬测叠谤测迟别鈩�-笔濒补迟迟蹿辞谤尘 voran, um dem wachsenden Bedarf an Behandlungen f眉r seltene Krankheiten gerecht zu werden, wobei der Fokus speziell auf dem kutanen T-Zell-Lymphom (CTCL) liegt, einer seltenen Hautkrebserkrankung, die haupts盲chlich 盲ltere Erwachsene betrifft. Das Unternehmen hat erfolgreich die Herstellung des Wirkstoffs von HyBryte in den USA etabliert.
Diese Entwicklung steht im Einklang mit Gesundheitsinitiativen, die darauf abzielen, den Zugang zu Behandlungen zu verbessern und medizinische Innovationen zu beschleunigen 鈥� besonders relevant, da 眉ber 30 Millionen Amerikaner mit seltenen Krankheiten leben. Der Fokus des Unternehmens auf CTCL stellt einen strategischen Schritt dar, um ein unterversorgtes therapeutisches Gebiet anzugehen, was angesichts der alternden US-Bev枚lkerung und der Herausforderungen bei der Diagnose seltener Krankheiten bei Senioren von besonderer Bedeutung ist.
- Successful establishment of U.S.-based manufacturing for HyBryte's active ingredient
- Strategic positioning in underserved CTCL market with high growth potential
- Alignment with government healthcare initiatives for rare disease treatments
- Early stage of commercialization with no revenue generation yet
- Operating in highly competitive pharmaceutical market
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via 鈥� Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by ("NNW"), one of 70+ brands within聽the聽@听(), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, 鈥淟ate-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,鈥� please visit:
As America鈥檚 population ages, chronic and rare diseases are emerging as a pressing healthcare challenge 鈥� one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration鈥檚 鈥淢ake America Healthy Again鈥� initiatives have emphasized improving access to treatments and accelerating medical innovation.
Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte鈥檚 active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population.
About Soligenix Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (鈥淪GX301鈥� or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (鈥淐TCL鈥�). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (鈥淪GX302鈥�) into psoriasis, the company鈥檚 first-in-class innate defense regulator (鈥淚DR鈥�) technology, dusquetide (鈥淪GX942鈥�) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (鈥淪GX945鈥�) in Beh莽et鈥檚 disease.
The company鈥檚 Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company鈥檚 vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix鈥檚 vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (鈥淣IAID鈥�), the Defense Threat Reduction Agency (鈥淒TRA鈥�) and the Biomedical Advanced Research and Development Authority (鈥淏ARDA鈥�).
For further information, visit the company鈥檚 website at聽.
NOTE TO INVESTORS:聽The latest news and updates relating to SNGX are available in the company鈥檚 newsroom at聽
About NetworkNewsWire
听(鈥淣NW鈥�) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within聽the聽听蔼听聽that delivers:听(1) access to a vast network of wire solutions via聽InvestorWire聽to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;听(2) article and聽;听(3) 聽to ensure maximum impact;听(4)聽聽via IBN to millions of social media followers;聽and (5) a full array of tailored聽. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today鈥檚 market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit聽
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished:
NetworkNewsWire
New York, NY
212.418.1217 Office
NetworkNewsWire is powered by聽
FAQ
What is Soligenix's (SNGX) main product development focus?
Where is Soligenix (SNGX) manufacturing HyBryte's active ingredient?
What market opportunity is Soligenix (SNGX) targeting with HyBryte?
How does Soligenix's (SNGX) HyBryte align with current healthcare initiatives?
What patient population does Soligenix (SNGX) target with HyBryte?
